Measles-Mumps-Rubella-Varicella Combination Vaccine (ProQuad®): A Guide to Its Use in Children in the EU

    loading  Checking for direct PDF access through Ovid

Abstract

In the EU, the live attenuated, tetravalent measles-mumps-rubella-varicella vaccine ProQuad® is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age using a two-dose schedule and may be used in infants from 9 months of age to conform with a national vaccination schedule, outbreak situations or travel to a region with a high prevalence of measles. Clinical data in young children indicates that vaccination with ProQuad® is as immunogenic as the component vaccines, provides long-term protection against these potentially serious childhood infections and has an acceptable safety profile. Combining the viral strains of the measles-mumps-rubella vaccine M-M-RVAXPRO® and the varicella vaccine Varivax® in ProQuad® reduces the complexity of vaccination schedules, thereby potentially improving vaccination coverage and the timeliness of vaccination.

Related Topics

    loading  Loading Related Articles